Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
SpyGlass Pharma reported a net loss of $57.9 million for the nine months ended September 30, 2026, compared to $27.3 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through an initial public offering and the conversion of preferred stock, ending the period with $208.7 million in cash and cash equivalents.
M2i Global Signs $100M M&A Deal with Happy Growth Group Limited
M2i Global entered into a definitive agreement to acquire 100% of Graphex Technologies LLC (GTL) from Happy Growth Group Limited for $100 million. The purchase price consists of $3 million in cash (via a note) and $97 million in common stock tranches tied to the delivery of a design and completion of a 50,000 metric ton per year graphite anode production plant in the U.S. The acquisition includes an exclusive license to 30 patents for natural graphite anode production across North America.
HeartCore Enterprises Partnership with ONE AI Co., Ltd.
HeartCore Enterprises entered into a non-exclusive business development and sales agency agreement with ONE AI Co., Ltd. to bring the Axis.ONE physical AI platform to industrial robots in Japan. The partnership aims to retrofit existing factory equipment with CPU-native, on-device AI capabilities for vision and decision-making without requiring GPU clusters or cloud dependency.
GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.
VisionWave Holdings Signs $7M M&A Deal with Europostachservice LLC
VisionWave Holdings entered into a non-binding Letter of Intent to acquire a 51% controlling interest in EPSERVICE, a Ukrainian developer of unmanned aerial systems and 'mothership' drone control technology. The proposed acquisition from Metal Machinery Components Trading – FZCO involves $7 million in cash consideration payable 90 days after closing. The deal is subject to technical due diligence in Ukraine, including a live flight demonstration of the ICMM system.
Talen Energy Wins $700M Contract from investment grade counterparty in PJM
Talen Energy's subsidiaries Guernsey Power Station and Waterford Power entered into capacity sale transactions with an investment grade counterparty in the PJM market. The primary Guernsey 7-Year Capacity Sale covers 750 MW of capacity from 2029 through 2036 and is expected to generate approximately $100 million in annual revenue.
Incannex Healthcare Inc. reported a net loss from operations of $3.44 million for the quarter ended September 30, 2026, an improvement from a $6.79 million loss in the prior year period, primarily due to reduced general and administrative expenses. The company maintained a strong cash position of $68.27 million and continues to focus on its clinical development pipeline, including drug candidates IHL-42X and IHL-675A.
Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.
Term
4 weeks
“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”
Adam Mendelsohn, PhD, CEO
“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”
Perspective Therapeutics CEO Johan M. Spoor Buys $37.9K of Stock
Johan M. Spoor, CEO, bought 47,000 shares of Perspective Therapeutics, Inc. at $0.8073 a share, worth $37.9K in total on Nov 11, 2026. Shares held after the trade: 106,383 (+79.1%).
New Era Energy & Digital (NUAI) is transitioning from a site-only play to an execution-ready data center developer with 757MW capacity and key permits secured.
SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.
Term
Q3 2026
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”
Patrick Mooney, chief executive officer of SpyGlass Pharma
Ondas reported record Q3 2026 revenue of $167.5 million, representing a 100% sequential increase and a 16-fold increase year-over-year. The company raised its full-year 2026 revenue target to at least $550 million and initiated a 2027 revenue target of at least $1.1 billion, driven by strong bookings and backlog growth.
“This quarter demonstrates the growing benefits of Ondas’ integrated operating platform. Our businesses are gaining access to larger customers, broader channels, and stronger production and field-support capabilities, allowing mission-ready technologies to move more quickly from evaluation into deployment.”
Eric Brock, Chairman and CEO of Ondas
“We expect a strong finish to 2026, with momentum accelerating in the fourth quarter as volume deliveries ramp across existing programs and we convert pipeline opportunities into customer programs.”
Clarivate $533M Debt Financing with Clarivate Science Holdings Corporation
Clarivate Plc announced the final results of cash tender offers to purchase its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The company increased the acceptance amount and will purchase a total aggregate principal amount of $533 million of the notes. The 2028 and 2029 notes were accepted at proration factors of approximately 67.9% and 45.5%, respectively.
Cornerstone Building Brands $500M Debt Financing with Monarch Alternative Capital LP
Cornerstone Building Brands entered into a $500 million term loan facility led by Monarch Alternative Capital LP to support operations and enhance liquidity. Separately, the company reached a non-binding agreement in principle with an ad hoc group of creditors holding 54% of its debt for a comprehensive recapitalization transaction supported by its equity sponsor, CD&R.
CorMedix Inc. reported net income of $49.9 million for the nine months ended September 30, 2026, a decrease from $149.0 million in the prior year period, primarily due to higher operating expenses and a significant tax benefit recorded in 2025. Total revenue and grant income grew to $283.9 million for the nine-month period, driven by product sales and new grant income.
Intuitive Surgical EVP & Chief Legal and Complian Gary Loeb Sells $183K of Stock
Gary Loeb, EVP & Chief Legal and Complian, sold 400 shares of Intuitive Surgical Inc at $458.15 a share, worth $183K in total on Nov 10, 2026. Shares held after the trade: 6,236 (-6.0%).
Corvex, Inc. reported third quarter 2026 financial results, its first full period following the divestiture of legacy healthcare assets. The company reported revenue of $5.0 million and a net loss of $17.5 million as it transitions to an AI computing platform model.
Term
Q3 2026
“We are building the Corvex AI Factory business one underwritten project at a time, and the third quarter moved that business forward. We have now secured all of the approximately 8 MW of critical IT capacity in the plan we set out in August.”
Jay Crystal, Co-Founder and Co-Chief Executive Officer
“Corvex is an engineering company first. In the third quarter we launched Corvex Token Factory on schedule and received notices of allowance for two patents covering Corvex’s technology, bringing our portfolio to two allowed patents and 10 pending patent applications.”
Seth Demsey, Co-Founder and Co-Chief Executive Officer
Leatt Corporation reported its highest quarterly revenues in four years, with Q3 2026 revenue increasing 43% to $20.46 million. Net income surged 309% to $2.20 million, driven by broad-based growth across body armor and helmet categories and the recoupment of global trade tariffs.
Term
Q3 2026
“The third quarter of 2026 was a strong quarter by nearly every measure. Total global revenues of $20.46 million were our highest in four years, up 43% over the third quarter of 2025.”
Sean Macdonald, Chief Executive Officer
“Net income for the third quarter increased by 309% to $2.20 million as compared to the third quarter of 2025. Gross profit increased by 48% to $9.32 million, in part due to the recoupment of global trade tariffs levied on the importation of goods into the U.S.”
Leatt Corp reported strong growth for the third quarter of 2026, with revenues increasing 43% to $20.46 million and net income rising to $2.20 million compared to $0.54 million in the prior year period. For the nine months ended September 30, 2026, the company generated $4.59 million in net cash from operating activities and maintained a solid balance sheet with $15.43 million in cash and cash equivalents.
Filana Therapeutics appointed Jill M. Quigley to its Board of Directors as a Class I director, effective November 8, 2026. Ms. Quigley brings over 20 years of biopharma leadership experience, including previous CEO and COO roles at Genuiti Therapeutics and Passage Bio. Her appointment is intended to support the company as it prepares for a Phase 2a clinical study of simufilam in TSC-related epilepsy.
RUM Group reported record Q3 2026 revenue of $96.6 million, a 290% year-over-year increase driven by the first full quarter of Quake AI contributions. The company achieved its first-ever profitable quarter on an Adjusted EBITDA basis, supported by high utilization of its 22,000 NVIDIA GPU fleet.
Term
Q3 2026
“Q3 was a defining quarter for RUM Group. We delivered record revenue, nearly four times last year’s, and achieved positive Adjusted EBITDA for the first time in our history. Quake AI is now the engine of our business. We have real assets running real AI workloads for real customers and generating real cash. Our 22,000-GPU estate is nearly sold out at 85% utilization. As capital becomes more selective, we believe it will flow to experienced operators with disciplined balance sheets. That is exactly where RUM Group stands, and we intend to use that position to build lasting value for our shareholders.”
Sei Investments Insider William Doran Sells $882K of Stock
William Doran sold 8,000 shares of Sei Investments Co at $110.30 a share, worth $882K in total on Nov 10, 2026. Shares held after the trade: 630,802 (-1.3%).
Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.
SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.
Jorey Chernett bought 71,315 shares of Exagen Inc. at $5.23 a share, worth $373K in total on Nov 11, 2026. Shares held after the trade: 2,696,940 (+2.7%).
Trustmark Signs $3.2B M&A Deal with Hancock Whitney Corporation
Trustmark Corporation has entered into a definitive agreement to merge with and into Hancock Whitney Corporation in an all-stock transaction valued at approximately $3.2 billion. The merger will create a premier Gulf South regional bank with approximately $58 billion in assets and is expected to close in the first quarter of 2027.
SES AI Corp reported its Q3 2026 financial results, highlighting a 31% sequential revenue increase to $6.6 million and a narrowing GAAP net loss of $13.4 million. The company successfully ramped its Chungju production line to 1 million cells per year and introduced its 'Flywheel' strategy focusing on drones, energy storage, and material discovery.
Data443 Risk Mitigation announced the commercial launch of its Convaa.ai™ enterprise AI collaboration platform on the Apple App Store. The application is specifically optimized for the iPhone Duo foldable smartphone, allowing multi-person live AI collaboration sessions on the device's 7.6-inch inner display.
Suburban Propane Partners reported fiscal year 2026 net income of $109.0 million and Adjusted EBITDA of $284.0 million, a 2.2% increase over the prior year. The company highlighted strong heat-related demand in its propane segment and a 13% increase in average daily renewable natural gas (RNG) injections following facility upgrades and new capacity in New York.
Term
FY2026
“Fiscal 2026 was another strong year for Suburban Propane with solid results in our propane operations, the completion of capital projects to increase the scale of our renewable natural gas (“RNG”) business, and continued debt reduction to further strengthen our financial position.”
Michael A. Stivala, President and Chief Executive Officer
“With these investments in place, we enter fiscal 2027 with a larger, more reliable RNG platform, opportunities to increase production through capacity optimization and higher feedstock intake, and the ability to enhance our earnings profile from the recognition of additional PTCs.”
Michael A. Stivala, President and Chief Executive Officer